Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilja Spellmann

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Journal of Psychiatric Research|July 6, 2010
Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patientsIlja Spellmann, Dan Rujescu, Richard Musil, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 1, 2014
Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patientsIlja Spellmann, Dan Rujescu, Richard Musil, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 12, 2012
No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depressionRichard Musil, Peter Zill, Florian Seemüller, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 16, 2012
Genetics of emergent suicidality during antidepressive treatment--data from a naturalistic study on a large sample of inpatients with a major depressive episodeRichard Musil, Peter Zill, Florian Seemüller, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 28, 2014
What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trialRebecca Schennach, Michael Riedel, Michael Obermeier, et al.
International Journal of Methods in Psychiatric Research|July 17, 2015
Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change methodsRebecca Schennach, Hans-Jürgen Möller, Michael Obermeier, et al.
Psychiatry Research|March 17, 2012
One-year functional outcomes of naturalistically treated patients with schizophreniaIlja Spellmann, Michael Riedel, Rebecca Schennach, et al.
European Archives of Psychiatry and Clinical Neuroscience|August 30, 2019
What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trialRebecca Schennach, Michael Riedel, Michael Obermeier, et al.
Pharmacopsychiatry|May 16, 2017
Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder - When, Who, and How?Rebecca Schennach, Michael Obermeier, Florian Seemüller, et al.
European Archives of Psychiatry and Clinical Neuroscience|October 28, 2016
Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studiesIlja Spellmann, Rebecca Schennach, Florian Seemüller, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Journal of Psychiatric Research|July 6, 2010
Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patientsIlja Spellmann, Dan Rujescu, Richard Musil, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 1, 2014
Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patientsIlja Spellmann, Dan Rujescu, Richard Musil, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 12, 2012
No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depressionRichard Musil, Peter Zill, Florian Seemüller, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 16, 2012
Genetics of emergent suicidality during antidepressive treatment--data from a naturalistic study on a large sample of inpatients with a major depressive episodeRichard Musil, Peter Zill, Florian Seemüller, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 28, 2014
What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trialRebecca Schennach, Michael Riedel, Michael Obermeier, et al.
International Journal of Methods in Psychiatric Research|July 17, 2015
Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change methodsRebecca Schennach, Hans-Jürgen Möller, Michael Obermeier, et al.
Psychiatry Research|March 17, 2012
One-year functional outcomes of naturalistically treated patients with schizophreniaIlja Spellmann, Michael Riedel, Rebecca Schennach, et al.
European Archives of Psychiatry and Clinical Neuroscience|August 30, 2019
What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trialRebecca Schennach, Michael Riedel, Michael Obermeier, et al.
Pharmacopsychiatry|May 16, 2017
Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder - When, Who, and How?Rebecca Schennach, Michael Obermeier, Florian Seemüller, et al.
European Archives of Psychiatry and Clinical Neuroscience|October 28, 2016
Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studiesIlja Spellmann, Rebecca Schennach, Florian Seemüller, et al.
Pageof 4